These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16004669)

  • 1. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
    Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
    Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
    Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
    Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
    Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
    Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
    Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
    Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
    Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
    Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
    Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.
    Nevitt MC; Thompson DE; Black DM; Rubin SR; Ensrud K; Yates AJ; Cummings SR
    Arch Intern Med; 2000 Jan; 160(1):77-85. PubMed ID: 10632308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
    Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
    Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).
    Langdahl BL; Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Fahrleitner-Pammer A; Walsh JB; Barker C; Kutahov A; Marin F
    Calcif Tissue Int; 2009 Dec; 85(6):484-93. PubMed ID: 19823760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.